CD4 and myeloid sarcoma: Our findings are in agreement with Ciccocioppo et al 2019 who, like our study, found no difference in MS or HD in total CD4+CD25+CD127loTreg, but higher activated Treg (Population II, CD45RA−CD25hi) and lower resting Treg (Population I, CD45RA+CD25+) in MS37.